Brain-activating CAR-T therapy wipes out deadly childhood brain tumors in every mouse tested

Scientists at UC San Francisco have engineered a next-generation CAR-T cell therapy that only activates once it enters the brain — a design that allowed it to completely wipe out diffuse midline glioma (DMG) in every mouse tested. DMG is one of the most devastating childhood cancers, growing into the brainstem and killing nearly all patients within a year of diagnosis.

The therapy, called B-SYNC CAR-T, uses a molecular sensing system called synNotch that detects brevican — a protein naturally found throughout the brain — as its "on switch." Once inside the brain, the engineered immune cells begin producing cancer-targeting receptors and attacking tumor cells, while remaining inactive in the rest of the body. This targeted activation may also help prevent T cell exhaustion, keeping the cells functional and patrolling for cancer for over 70 days post-treatment.

Key Takeaways:

• B-SYNC completely eliminated DMG tumors in two mouse models via direct brain injection, outperforming conventional CAR-T cells
• Treated mice rejected a second round of cancer cells introduced ~7 weeks later, showing durable immune protection
• CAR activation was confined to the brain — cells in the blood and spleen did not produce cancer-targeting receptors
• Human trials at UCSF Health are planned to begin as early as April 2027, using each patient's own modified T cells

Why it matters: DMG is essentially untreatable today, with no effective therapies and a median survival under a year. B-SYNC's ability to eliminate tumors and provide lasting protection in preclinical models marks a significant leap forward — and the rapid move toward clinical trials signals real hope for children and families facing this devastating diagnosis.